Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 5331SC

5331SC 50 µg (With Carrier)
5331SF 50 µg (Carrier Free)
5331LC 250 µg (With Carrier)
5331LF 250 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant mouse EGF (mEGF) Asn977-Arg1029 (Accession #NP_034243) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mEGF. All lots are greater than 98% pure.


Molecular Formula:

Recombinant mEGF has a Met on the amino terminus and has a calculated MW of 6045. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MNSYP of recombinant mEGF was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant mEGF was determined in an NIH/3T3 cell proliferation assay. The ED50 of each lot is between 40-250 pg/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg mEGF.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg mEGF. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

EGF is produced by epithelial cells, fibroblasts, and many other cell types (1,2). Low molecular weight soluble EGF is generated through proteolysis of a larger ~130,000 molecular weight transmembrane precursor (1,2). Both soluble and membrane forms of EGF are active (2). EGF induces proliferation, differentiation, and survival of many cell types including tumor-derived cells (1-3). There are multiple members of the EGF family and multiple members of the ErbB/HER EGF receptor family. EGF binds to ErbB1/HER1 and induces homodimerization or induces heterodimerization with other ErbB/HER members (1).  Binding of EGF signals through the MAPK, PI3K/Akt, and Stat5 pathways (1). EGF, EGF family members, EGF receptors, and their signaling pathways are involved in many cancers and are targets for therapeutic intervention (1, 2).


1.  Citri, A. and Yarden, Y. (2006) Nat Rev Mol Cell Biol 7, 505-16.

2.  Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.

3.  Xian, C.J. (2007) Endocr Rev 28, 284-96.


Entrez-Gene Id 13645
Swiss-Prot Acc. P01132


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.